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ABSTRACT
Objective: To elaborate recommendations for the treatment of rheumatoid arthritis in Brazil. Method: Literature re-
view with articles’ selection based on evidence and the expert opinion of the Rheumatoid Arthritis Committee of the 
Brazilian Society of Rheumatology. Results and conclusions: 1) The therapeutic decision should be shared with the 
patient; 2) immediately after the diagnosis, a disease-modifying antirheumatic drug (DMARD) should be prescribed, 
and the treatment adjusted to achieve remission; 3) treatment should be conducted by a rheumatologist; 4) the initial 
treatment includes synthetic DMARDs; 5) methotrexate is the drug of choice; 6) patients who fail to respond after 
two schedules of synthetic DMARDs should be assessed for the use of biologic DMARDs; 7) exceptionally, biologic 
DMARDs can be considered earlier; 8) anti-TNF agents are preferentially recommended as the initial biologic therapy; 
9) after therapeutic failure of a ﬁ rst biologic DMARD, other biologics can be used; 10) cyclophosphamide and azathio-
prine can be used in severe extra-articular manifestations; 11) oral corticoid is recommended at low doses and for short 
periods of time; 12) non-steroidal anti-inﬂ ammatory drugs should always be prescribed in association with a DMARD; 
13) clinical assessments should be performed on a monthly basis at the beginning of treatment; 14) physical therapy, 
rehabilitation, and occupational therapy are indicated; 15) surgical treatment is recommended to correct sequelae; 16) 
alternative therapy does not replace traditional therapy; 17) family planning is recommended; 18) the active search and 
management of comorbidities are recommended; 19) the patient’s vaccination status should be recorded and updated; 
20) endemic-epidemic transmissible diseases should be investigated and treated
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INTRODUCTION 
Rheumatoid arthritis (RA) is a systemic inﬂ ammatory autoim-
mune disease that affects the synovial membrane of peripheral 
joints. Its prevalence is estimated at around 0.5%–1% of the 
population, predominantly in women, and higher incidence in 
the age group from 30–50 years.1,2
The main characteristic of RA is the symmetrical im-
pairment of small and large joints, with a more frequent 
involvement of the hands and feet. The chronic and de-
structive character of the disease can lead to important 
functional limitation, with loss of work capacity and 
quality of life, unless the diagnosis is established at an 
early phase of the disease and clinical improvement results 
from treatment.3 In addition to irreversible deformity and 
functional limitation, patients with RA and advanced dis-
ease can have a shorter survival, confirming the severity 
of that disease.4,5 
The costs related to RA are high, resulting from both 
direct (expenditure with several medications, some of which 
are expensive, such as biologic drugs, in addition to medical 
and hospital costs) and indirect (loss of personal productivity, 
absenteeism, and retirement due to disability for those with 
total work capacity loss) factors. 6 
Over the past 10 years, the knowledge about the pathophysi-
ological  mechanisms of RA has advanced dramatically, with 
the development of new therapeutic classes of drugs and the 
implementation of different strategies of treatment and follow-
up, such as intensive control of the disease and intervention 
at the beginning of the symptoms.7 The initial period of the 
disease, especially its ﬁ rst 12 months (the so-called early RA),5 
is considered a therapeutic window, that is, when prompt and 
effective pharmacological intervention can change the disease 
course in the long run. Those factors have resulted in RA better 
clinical control, with the possibility of its sustained remission.7,8
The present consensus aimed at elaborating recom-
mendations for the management of RA, with an emphasis 
on treatment, considering peculiar aspects of the Brazilian 
socioeconomic reality. The purpose of this document was 
to synthesize the current position of the Brazilian Society of 
Rheumatology (BSR) about the subject, aiming at better edu-
cating Brazilian physicians, especially rheumatologists, on the 
rational therapeutic management of RA in Brazil. 
METHOD OF CONSENSUS BUILDING
The method of consensus building for the development of 
recommendations included literature review and consultation 
of the opinion of the BSR Rheumatoid Arthritis Committee 
expert members. The bibliographic survey comprised 
publications in the MEDLINE, SciELO, PubMed, and 
EMBASE bases up to November 2011. The recommenda-
tions have been written and reassessed by all participants 
during ﬁ ve meetings held on October and December 2010, 
and February, July and October 2011, in addition to sev-
eral rounds of questionings and corrections conducted via 
Internet. 
TREATMENT OF RHEUMATOID ARTHRITIS
The RA treatment comprises education of patients and their 
families, medicamentous therapy, physical therapy, psycho-
social support, occupational therapy and surgical approaches. 
The medicamentous therapy includes the use of nonsteroidal 
anti-inﬂ ammatory drugs (NSAIDs), corticoids, synthetic and 
biologic disease-modifying antirheumatic drugs (DMARDs), 
and immunosuppressive drugs.
Educational measures
Before starting any form of treatment, patients should be edu-
cated about their disease, and, particularly, about its possible 
evolution, therapy and prognosis. They should be instructed 
about inadequate information provided through several com-
munication media, especially the Internet. Education should 
start on the ﬁ rst consultation and include the family members, 
so that all of them can share information on the disease, which 
results in better management of the medicamentous and non-
medicamentous treatments.9,10 
Educational activities are essential to guarantee patients’ 
collaboration. Patients have the right to know about their health 
conditions and the available therapeutic options, and actively 
participate in the choices. Patients who understand their con-
ditions and know about the medications action, the methods 
to prevent deformities, and the rehabilitation process, have a 
better clinical evolution.11 
Patients should be instructed about the role played by 
exercises and joint protection, and speciﬁ c techniques of 
physical therapy and rehabilitation, so that they can get more 
involved with such activities to prevent joint deformities. In 
addition, they should be educated about the possible adapta-
tion of household appliances and modiﬁ cations in the work 
environment.12 
Because patients with RA are often followed up by a mul-
tidisciplinary team, all professionals should have the same 
objectives and work together harmoniously.13
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Medicamentous treatment
Nonsteroidal anti-inﬂ ammatory drugs – NSAIDs
The NSAIDs are useful to reduce the inﬂ ammatory process and 
pain, mainly at the early phase of disease, because DMARDs 
do not act immediately. In addition, NSAIDs can be used 
when complete control of disease activity is not achieved and 
in disease relapse.14,15
The choice of NSAIDs should be individualized, be-
cause there is no known superiority of any drug in that 
class. More control, substitution, suspension, shorter use, 
and lower doses should be considered in the presence of 
clinical conditions that can be aggravated by NSAIDs, 
such as previous hypersensitivity to NSAIDs, systemic 
arterial hypertension (SAH), heart failure, renal failure, 
gastrointestinal disease, arterial failure, hepatopathy, and 
coagulation disorders.16
For patients with previous history of gastrointestinal dis-
ease, selective cyclooxygenase 2 inhibitors have lower risk as 
compared with other NSAIDs.17 For those at greater risk for 
cardiovascular disease, the use of anti-inﬂ ammatory drugs in 
general should be cautious.18
Corticoids
The most known and expected effect of corticoids in RA 
is the improvement in the inﬂ ammatory process and pain. 
However, there is current evidence for their indication as 
participants in the disease course modiﬁ cation in association 
with DMARDs.19,20
Most studies on the use of corticoids for the treatment of 
RA have suggested the use of prednisone or prednisolone 
at low doses (≤ 15 mg/day). There are no comparative studies 
indicating the preferential use of higher doses at the beginning 
of treatment.19,20 
Because corticoids can cause several side effects, their 
use should be shortened as much as possible. If the corticoid 
administration is expected to last three or more months, cal-
cium and vitamin D supplementation should be performed. 
Depending on the bone densitometry result, and in patients 
with risk factors for fractures, the use of antiresorptive drugs, 
such as bisphosphonates, can be considered.21 In patients who 
maintain active disease in few joints, intraarticular corticoid 
can be used at any time during treatment22 – nevertheless, 
one joint should not be inﬁ ltrated more than three to four 
times a year. In patients using concomitantly corticoid and 
NSAIDs, gastric protection with proton pump inhibitors is 
recommended.22
Disease-modifying antirheumatic drugs – DMARDs
The DMARDs should be indicated to patients from the time 
RA is diagnosed.23 The use of DMARDs in patients with undif-
ferentiated arthritis and biomarkers for RA, such as positivity 
for anti-cyclic citrullinated peptide antibody (anti-CCP) and/
or rheumatoid factor (RF), should be considered.24
Table 1 shows the most often used DMARDs in Brazil, 
their presentation, dosage, and considerations about treatment 
monitoring. 20,25–94
Synthetic DMARDs
a) Methotrexate – MTX
MTX is an immunomodulatory agent, which inhibits the synthesis 
of DNA, RNA, thymidine, and proteins. The anti-inﬂ ammatory 
effects of MTX on RA seem to be related, at least partially, to the 
modulation of the adenosine metabolism, and to other possible 
effects on the tumor necrosis factor (TNF) pathways. The im-
munosuppressive and toxic effects of MTX are due to the inhibi-
tion of dihydrofolate reductase, the enzyme involved in the folic 
acid metabolism, which prevents the reduction of dihydrofolate 
to active tetrahydrofolate. Maximum concentration is obtained 
in 1–5 hours, by oral administration, and in 30–60 minutes by 
intramuscular (IM) or subcutaneous (SC) routes. Renal excretion 
of 40% to 90% of MTX in its unaltered form occurs.25
MTX is currently considered the ﬁ rst choice for treating 
RA.26 Its capacity to reduce signs and symptoms of RA activ-
ity and improve the patient’s functional status has been dem-
onstrated.27 In addition, MTX reduces radiographic disease 
progression. 
The initial MTX dose recommended is 10–15 mg/week, by 
oral or parenteral administration (IM or SC). If neither disease 
improvement nor disease control is observed with the initial 
dose, it should be progressively increased every 2–4 weeks 
until reaching the dose of 20–30 mg/week, preferentially in the 
ﬁ rst 12 weeks. The parenteral administration can be indicated to 
patients with gastrointestinal intolerance or with an inadequate 
response to the oral administration.28
The most frequently observed side effects are as follows: 
anemia, neutropenia, nausea and vomiting, mucositis, and an 
elevation in liver enzymes. Interstitial pneumonia is a less 
frequent manifestation. To minimize side effects, folic acid 
should be associated with MTX, at the dose of 5–10 mg/week, 
and administered 24–48 hours after MTX.28 To patients with 
renal failure, liver disorders, alcoholism, and bone marrow 
suppression, in addition to women of childbearing age who are 
not using contraception, MTX is contraindicated. Pregnancy 
and breast-feeding are formally contraindicated to patients on 
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MTX, which should be cautiously administered to patients with 
mild lung disorders, and avoided in individuals with moderate 
or severe lung impairment.28 
b) Sulfasalazine – SSZ
SSZ belongs to the group of salicylates and sulfonamides, being 
metabolized by intestinal bacteria to sulfapyridine and 5-amino-
salicylic acid. Sulfapyridine has several immunomodulatory ef-
fects, such as the inhibition of prostaglandin production, of several 
neutrophilic and lymphocytic functions, and of chemotaxis. It also 
inhibits folate-dependent enzymes. Its serum concentration peaks 
in approximately 1.5–6 hours, and its half-life is of 5–10 hours. 
SSZ is metabolized in the gastrointestinal tract (by the intestinal 
ﬂ ora), and excreted through the kidneys (75%–91%).29
SSZ is considered more effective than placebo in reduc-
ing disease activity, controlling pain, and for global clinical 
assessment. Its clinical efﬁ cacy and the interference with the 
radiographic disease progression are conﬁ rmed.29 It is usually 
prescribed at the dose of 1–3 g/day, orally.29,30
The side effects of SSZ are as follows: gastrointestinal intol-
erance (anorexia, nausea, vomiting), skin rash, elevation in liver 
enzymes, oral ulcers, and myelosuppression (leukopenia with 
neutropenia). More rarely, hypersensitivity pneumonia, neuro-
logical manifestations, and male fertility changes are observed. 
Most effects are benign and are reversed with drug suspension.30
SSZ is contraindicated in patients with history of hyper-
sensitivity to sulfa drugs, salicylates or any component of the 
SSZ formula, and in individuals with porphyria.29,30
c) Leﬂ unomide – LEF 
LEF is an immunomodulatory agent with antiproliferative 
activity that inhibits the enzyme dihydroorotate dehydro-
genase, which is involved in pyrimidine synthesis. LEF is 
absorbed through the gastrointestinal tract, and its biotrans-
formation probably occurs in the liver and gastrointestinal 
wall, where LEF is mainly transformed into M1, the active 
metabolite responsible for all the drug’s effects. The con-
centration of M1 peaks in 6–12 hours, and that metabolite 
is eliminated through the kidneys and intestines.31
LEF improves disease activity and quality of life, and re-
duces the radiographic disease progression.32,33 It is prescribed 
at the dose of 20 mg/day, orally,31–33 but 20 mg on alternate 
days can be used.
The side effects of LEF include nausea, vomiting, abdominal 
pain, diarrhea, changes in liver enzymes, skin rash, and SAH.31 It 
is contraindicated to women of childbearing age who are not using 
contraception, and to patients with renal failure and liver disor-
ders. Pregnancy and breast-feeding are formally contraindicated 
to patients on LEF. Its suspension is recommended two years 
before a possible pregnancy. In case of incidents, especially dur-
ing pregnancy, LEF can be eliminated by using cholestyramine, 
at the dosage of 8 g, three times a day, for 11 days.31
d) Antimalarials (chloroquine diphosphate – CQD and hy-
droxychloroquine sulfate – HCQ) 
Antimalarials have been used in the treatment of RA for over 
50 years. They are safe and effective, mainly in the early 
and mild forms of the disease. The mechanism of action is 
not completely understood, but it seems to involve multiple 
factors, such as anti-inﬂ ammatory activity (stabilization of 
lysosomal membranes, and inhibition of lysosomal enzymes, 
and of polymorphonuclear chemotaxis and phagocytosis), and 
interference with prostaglandin production.34,35
The two available forms of antimalarials are CQD and 
HCQ, the latter being preferred due to its better safety proﬁ le, 
especially the ophthalmologic one. The maximum daily dose 
of CQD is 4 mg/kg/day, and of HCQ is 6 mg/kg/day, orally. 
The drug takes a while to start acting, requiring 3–4 months to 
reach its peak efﬁ cacy in approximately 50% of the patients.
The side effects vary and comprise the following: gas-
trointestinal intolerance (nausea, vomiting, abdominal pain), 
skin hyperpigmentation, headache, dizziness, myopathy, and 
retinopathy. The last side effect is not frequent, but regular 
ophthalmologic monitoring is indicated (initial assessment, 
annual assessment after ﬁ ve years, or annual assessment since 
the beginning, in the presence of risk factors, such as renal or 
liver dysfunction, maculopathy, advanced age, or cumulative 
dose greater than 1,000 g for HCQ or 460 g for CQD).36
As compared with placebo, HCQ is effective, reducing the 
clinical and laboratory parameters (erythrocyte sedimentation 
rate, ESR) analyzed, although, in isolation, it has not changed the 
radiographic disease progression.34,35,37 Similar results have been 
reported with CQD, which is less expensive. Both are contraindi-
cated in patients with alterations of the retina and visual ﬁ eld.36,37
Although antimalarials have been traditionally used in 
Brazil, often in association with other DMARDs, they are cur-
rently considered less potent drugs, and should be used for early 
RA or undifferentiated arthritis, with low erosive potential.
e) Gold salts 
Gold salts, speciﬁ cally the injectable forms (aurothioglucose 
and aurothiomalate), can both reduce constitutional and articular 
symptoms and slow the radiographic progression of RA.38 They 
can be used in monotherapy or combined with other agents.39
Their usual dose is 50 mg/week, usually beginning with 
25 mg/week. The intervals between applications can be increased 
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to fortnightly and monthly doses after disease control. The cu-
mulative dose should not exceed 3 g.38,39 Their toxicity proﬁ le 
includes myelotoxicity (mainly thrombocytopenia), oral ulcers, 
skin reactions (exfoliative dermatitis), nephropathy (nephrotic 
proteinuria can occur), and interstitial pulmonary disease.38,39
Although they have been mentioned in recent international 
recommendations,20 gold salts are currently rarely used in Brazil, 
due to their side effects and restricted availability in the country.
Biologic DMARDs
One of the most relevant advances in the therapy of RA was 
the development of biologic DMARDs.40 Although they are 
effective in controlling RA, their long-term safety has not 
been established.41
The following biologic DMARDs have been approved by 
the Brazilian Agency of Sanitary Surveillance (ANVISA) to 
be used in Brazil:42
l  Anti-TNF agents: adalimumab, certolizumab, etanercept, 
inﬂ iximab, and golimumab;
l  B lymphocyte depletion agent: rituximab;
l  T lymphocyte costimulation inhibitor: abatacept;
l  Interleukin-6 (IL-6) receptor blocker: tocilizumab.
Biologic DMARDs are indicated to patients with persistent 
disease activity, despite the treatment with at least two sched-
ules of synthetic DMARDs, of which at least one of them is 
a combination of DMARD. Biologics should be associated 
with a DMARD, preferably MTX. Exceptionally, as discussed 
below, a biologic DMARD can be prescribed earlier in the 
course of the treatment for RA, especially in cases of disease 
with signs of poor prognosis (high number of involved joints, 
radiographic erosions at the initial phase of disease, and high 
titers of RF and/or anti-CCP).13,20,43–46 
Social/educational/demographic characteristics of the dif-
ferent Brazilian macroregions, such as the difﬁ culty in the SC 
administration of medications experienced by some patients 
and their families, and the lack of infusion centers for the ad-
ministration of intravenous (IV) medication in certain areas, 
can determine the choice of one or other biologic DMARD. 
The public or private centers of drug dispensation/infusion 
should instruct patients and their families about the adequate 
storage of each drug, or send them directly to infusion sites, 
to prevent loss of treatment efﬁ cacy. It is recommended that 
rheumatologists indicate and monitor the use of those drugs.47 
Biologic DMARDs should not be associated because of the 
potential risk of severe infections.48,49 Currently, anti-TNF agents 
are the most used biologic DMARDs, but there are evidences 
that the other biologic DMARDs also control RA signs and 
symptoms and inhibit the radiographic disease progression.
a) Anti-TNF agents
TNF is a potent inﬂ ammatory cytokine expressed in large 
amounts in the serum and synovial ﬂ uid of individuals with 
RA. It causes the release of other inﬂ ammatory cytokines, 
particularly interleukins IL-1, IL-6 and IL-8, and stimulates 
the production of proteases. The inhibition of TNF has proved 
to be an effective and rapid form to control disease activity.50
In terms of efﬁ cacy, there are no data conﬁ rming the supe-
riority of any of the ﬁ ve anti-TNF agents approved in Brazil 
for the treatment of RA.51,52
Anti-TNF agents should be used in association with MTX or 
other DMARDs, because their combined use proved to be safe 
and provided rapid beneﬁ t in controlling disease activity, as com-
pared with the use of anti-TNF as monotherapy. For patients with 
contraindications to the use of synthetic DMARDs, anti-TNF 
agents can be occasionally prescribed as monotherapy.46,53–63
l  Adalimumab – ADA
ADA is a human antibody against TNF, prescribed for SC ad-
ministration at the dose of 40 mg, once every two weeks.55,56,64–68
l  Certolizumab – CERT
CERT pegol is a Fab fragment of the humanized anti-TNF 
antibody, with high afﬁ nity with TNF, conjugated with two 
molecules of polyethylene glycol. It is prescribed for SC ad-
ministration at the dose of 400 mg every two weeks, in weeks 
0, 2 and 4, and, after that, at the dose of 200 mg every two 
weeks, or 400 mg every four weeks.61,62,69
l  Etanercept – ETN
ETN is a fusion protein composed of the soluble TNF receptor 
plus the Fc region of IgG, prescribed at a single weekly dose 
of 50 mg via SC administration.57,58,68,70
l  Inﬂ iximab – IFX
IFX is a chimeric human-mouse monoclonal anti-TNF antibody, 
prescribed at the initial dose of 3 mg/kg IV, followed by the same 
dose (3 mg/kg) in the second and sixth weeks, and then every 
eight weeks. In patients with insufﬁ cient response, the dose can 
be elevated to 5 mg/kg per infusion, or the interval between doses 
can be reduced. Higher doses offer little therapeutic beneﬁ t and 
greater risk of infectious complications, and, thus, should be 
avoided in the treatment of RA.54,59,63,68,71
l  Golimumab – GOL
GOL is a monoclonal human anti-TNF antibody administered 
at the dose of 50 mg, SC, once a month.60,72 
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l Adverse effects and contraindications of the anti-TNF 
agents
The adverse effects of the anti-TNF agents include infu-
sion reactions for the IV drugs (fever, shivering, chest 
pain, blood pressure oscillation, dyspnea, pruritus and/or 
urticaria) and manifestations on the injection sites for the 
SC drugs (erythema, pruritus, local pain, and/or urticaria). 
Those drugs increase the likelihood of the following: 
infections, especially in their first year of use, includ-
ing severe infections and those caused by intracellular 
pathogens (tubercle bacillus, listeria, histoplasma, atypical 
mycobacteria, and legionella); cardiac dysfunction; demy-
elinating diseases; autoimmune phenomena (autoantibody 
production); cutaneous vasculitis; interstitial lung disease; 
and occasional increased risk for lymphoma.68,73–75 Human 
anti-chimeric antibodies can result from the use of any 
drug in that class, but their effect on the efficacy of the 
therapy is uncertain.76,77 
The anti-TNF agents are contraindicated to women dur-
ing pregnancy or breast-feeding, and to patients with the 
following: New York Heart Association functional classes 
III and IV congestive heart failure, active infection or 
high risk for the development of infections (chronic ulcer 
of the lower limbs, septic arthritis in the last 12 months), 
recurring lung infections, multiple sclerosis, and current 
or previous diagnosis of neoplasia (less than five years). 
Patients should be carefully followed up, with assessment 
of possible signs of infection, which should be addressed 
immediately.73–75
b) Costimulation modulator
l  Abatacept – ABAT
ABAT is a fusion protein CTLA-4-IgG that inhibits T lym-
phocyte costimulation. It is indicated to patients with active 
RA who failed a DMARD or anti-TNF agents. It can be used 
in association with DMARDs or in monotherapy. ABAT 
should be administered in IV infusion, for 30 minutes, at the 
dose of 500 mg in patients weighing less than 60 kg, 750 mg 
in patients weighing 60–100 kg, and 1,000 mg in patients 
weighing over 100 kg. The next dose should be administered 
two to four weeks after the initial dose, and, then, every four 
weeks.78–80
The use of ABAT has been associated with higher occur-
rence of infectious complications as compared with placebo, 
similarly to that observed with other biologic DMARDs. 
Infusion reactions with ABAT are rare, being mainly hypersen-
sitivity reactions that manifest as exanthem or bronchospasm. 
It is contraindicated for patients with chronic obstructive 
pulmonary disease, because of the exacerbation of dyspnea 
and greater occurrence of infections.78,81
c) B lymphocyte depletion agent
l  Rituximab – RTX 
RTX is a monoclonal chimeric antibody directed against 
CD20+ lymphocyte, indicated for patients with RA of moder-
ate to severe activity, who failed to respond to an anti-TNF 
agent. RTX is administered at the dose of 1,000 mg in two 
IV infusions at a 14-day interval. Sixty minutes before each 
infusion, 100 mg of methylprednisolone, IV, and 1 g of 
paracetamol and an antihistamine should be administered to 
reduce the severity and frequency of infusion reactions.82–85
RTX is preferentially used in association with MTX, and 
can be prescribed in association with other DMARDs. It is 
worth noting that a three to four month delay can occur until 
symptom improvement is observed.82–84 Individuals with posi-
tive serology for RF and/or anti-CCP show better therapeutic 
response to RTX.86 Individuals with good therapeutic response 
to RTX can undergo a new course of RTX in case of disease 
reactivation, at a time interval no shorter than six months.82–85
The most frequent adverse events are infusion reactions, 
which affect 35% of the patients at the ﬁ rst infusion and ap-
proximately 10% at the second infusion. In addition, infec-
tious complications, interstitial pneumonia, neutropenia, and 
thrombocytopenia can occur.82–85
d) Interleukin-6 receptor blocker
l  Tocilizumab – TOCI
TOCI is a humanized monoclonal antibody that binds the IL-6 
receptor, inhibiting the biologic effect of IL-6. It can be used as 
monotherapy, or in association with MTX or other DMARDs. 
The incidence of infections and severe infections is equivalent 
to that of other biologic agents. It is prescribed at the dose of 
8 mg/kg, IV, every four weeks.87–89
The dose-dependent side effects of the use of TOCI are as 
follows: neutropenia; thrombocytopenia; elevation in trans-
aminases, total cholesterol, and low-density lipoprotein; and 
increased occurrence of infections.87–89 It should be avoided in 
patients at higher risk for intestinal perforation, such as those 
with diverticular disease of the colon.90
Infection in patients on biologic DMARDs
Screening for infectious diseases is recommended before 
beginning biologic DMARDs, including thorough clinical as-
sessment, serologies for hepatitis B and hepatitis C, and, when 
pertinent, HIV and/or other endemic diseases. Screening for 
endemic diseases is better detailed below.
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Immunosuppressive drugs
The use of immunosuppressive drugs for the treatment of RA is 
based on the evidence of multiple immune mechanisms mediating 
the synovitis and other extra-articular manifestations of the disease.
Several mechanisms of action have been described, such as 
the reduction in cell response (and, less effectively, in humoral 
response) and anti-inﬂ ammatory properties (interference with the 
migration and action of neutrophils, lymphocytes and monocytes).
The use of immunosuppressive drugs is restricted to the 
most severe forms of RA, because most of such drugs are 
considerably toxic (severe myelosuppression, increased occur-
rence of infections, sterility, urinary bladder toxicity, increased 
occurrence of neoplasias).
Azathioprine – AZA
Despite its acceptable safety proﬁ le, its action as a DMARD 
remains controversial. AZA is considered a therapeutic option;91 
its lower effect on the control of signs and symptoms and the lack 
of proof on reduction of the radiographic disease progression, 
however, make it an alternative only for exceptional cases.20 
The usual dose of AZA is 1–3 mg/kg/day, orally. It is used 
for treating moderate to severe RA, refractory to other treat-
ments, or for controlling severe extra-articular manifestations, 
such as vasculitis.20,91
Cyclophosphamide – CF
An alkylating agent with an unfavorable toxicity proﬁ le and 
limited beneﬁ t in controlling synovitis, CF can be used either 
orally (1–2 mg/kg/day) or preferably IV (pulses of 0.5–1 g/m2 of 
body surface). Its use is justiﬁ ed only in severe extra-articular 
forms, mainly vasculitis.92
Cyclosporine – CS
CS is an effective alternative to control the signs and symptoms 
of RA. It can slow the progression of joint damage even in 
patients with severe RA refractory to other treatments, although 
its effect seems to be inferior to that of MTX, SSZ and LEF. 
It can be used as monotherapy, but is usually prescribed in 
association with MTX.20,93,94
Immunomodulation relatively speciﬁ c to T-lymphocyte has 
been proposed as the mechanism of action of cyclosporine. It 
is prescribed orally at the dose of 3–5 mg/kg/day. Cyclosporine 
is contraindicated in patients with altered renal function, un-
controlled hypertension, and malignancies. Its toxicity, how-
ever, limits its use to patients with disease non-responsive to 
other DMARDs, making it a drug that should only be used in 
exceptional circumstances for the treatment of RA. It is used 
preferentially in patients with extra-articular manifestations, 
such as vasculitis, being a safe alternative for patients with liver 
disorders and lung involvement. If hypertension or a 30%-in-
crease in baseline creatinine occurs, the cyclosporine dose 
should be reduced by 25%–50%. If hypertension or increased 
creatinine persists, the treatment should be discontinued.20,93,94
THERAPEUTIC STRATEGIES FOR THE 
TREATMENT OF RA IN BRAZIL
Disease-modifying antirheumatic drugs should be initiated im-
mediately after the diagnosis of RA. Whenever necessary, the 
treatment should be adjusted at frequent clinical assessments 
at 30–90-day intervals. 
Therapeutic strategies aimed at speciﬁ c goals produce 
better clinical outcomes and functional capacity, in addition 
to lower radiographic structural damage, as compared with 
conventional treatments.95 The goal is to reach remission, or 
at least low disease activity, assessed by use of compound 
indices of disease activity (CIDA), considering as therapeu-
tic response the reduction in CIDA, according to the 2011 
Brazilian Society of Rheumatology consensus for diagnosis 
and early assessment of RA.5 
Figure 1 depicts the ﬂ owchart of the medicamentous treat-
ment for RA in Brazil, proposed by the Rheumatoid Arthritis 
Committee of the Brazilian Society of Rheumatology.
First line – synthetic DMARDs
Methotrexate should be the ﬁ rst-choice DMARD.20,96,97 When 
contraindicated, SSZ98 or LEF99 can be used as the ﬁ rst op-
tion.100 The use of antimalarials (CQD and HCQ),101 can be 
indicated only for patients with mild disease or undifferenti-
ated arthritis with low erosive potential. In exceptional cases, 
such as patients with hypersensitivity to other DMARDs, or 
with viral hepatitis, gold salts can be used. MTX should be 
preferentially prescribed in monotherapy, at the beginning of 
treatment.102 
When the aimed clinical response (remission or low 
disease activity) is not obtained with the maximum tolerated 
dose of MTX, or in the presence of adverse effects, change 
to another DMARD as monotherapy or use of DMARD 
combinations is recommended. The most used combina-
tions of MTX are with the following: CQD/HCQ, SSZ,  an 
association of those three drugs,27 and LEF.103 The progres-
sion of therapy should be rapid, with monthly assessments 
in the ﬁ rst six months of treatment, and adjustment of the 
dosing schedules as required. A maximum period of six 
months should be observed to deﬁ ne lack of response to 
the ﬁ rst-line treatment instituted.20
Mota et al.
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Low doses of corticoids (maximum of 15 mg/day of pred-
nisone or equivalent), as well as anti-inﬂ ammatory drugs, can 
be used at the beginning of treatment; however, caution and 
the use for the shortest time possible to reduce the occurrence 
of adverse effects are recommended.20
Second line – biologic DMARDs
Immunobiologic therapy for RA is indicated for patients with 
persistently moderate to high disease activity (according to 
CIDA), despite the use of at least two of the schedules pro-
posed in the ﬁ rst-line treatment. Of the biologics, anti-TNF 
drugs are the ﬁ rst choice in Brazil after the schedules with 
synthetic DMARDs fail. That is justiﬁ ed by the more compre-
hensive post-commercialization experience, and the greater 
volume of safety information originating from national104 
and international20 clinical trials, registries, and recommenda-
tions. However, other drugs, such as ABAT and TOCI, can 
be prescribed at the physician’s discretion after failure of the 
synthetic DMARD, based on the publication of randomized 
clinical trials.78,89 RTX should be avoided as a ﬁ rst-choice 
biologic,20 except for the following speciﬁ c cases: patients 
with contraindication to other biologics, preferentially those 
positive to RF and/or anti-CCP, and those diagnosed with 
associated lymphoma.
On exceptional situations, a biologic DMARD can be 
indicated after failure of the ﬁ rst synthetic DMARD sched-
ule for patients with several factors of poor prognosis, such 
as very intense disease activity, elevated number of tender/
inﬂ amed joints, high titers of RF and/or anti-CCP, and early 
occurrence of radiographic erosions.20 The worse prognosis 
factors are better detailed in the 2011 Brazilian Society of 
Rheumatology Consensus for diagnosis and early assess-
ment of RA.5
Biologic DMARDs are not recommended as ﬁ rst-line 
treatment for RA in Brazil, because there is no evidence of 
cost-effectiveness in that country. 
Third line – failure of biologic DMARDs or 
intolerance to them
In the clinical settings of no response to the initial biologic 
treatment, evolution to loss of the response obtained, or 
presence of important adverse events, one biologic agent 
can be exchanged for another. The biologics that showed 
beneﬁ ts on randomized clinical trials with patients who 
failed anti-TNF agents were ABAT, RTX, and TOCI.105 
Patients who failed the ﬁ rst anti-TNF agent have also shown 
to beneﬁ t from the use of a second drug of the same class, 
such as ADA, CERT, ETN, IFX, or GOL, in prospective 
observational studies and also in double-blind controlled 
randomized trials (GOL), but the magnitude of their thera-
peutic effects and cost-effectiveness of that strategy remain 
controversial.106
The choice of the treatment sequence to be applied is at 
the physician’s discretion, depending on the particularities of 
each case. A minimum period of three months and maximum 
of six months of clinical assessment is recommended prior 
to exchanging the therapeutic schedule (exchange between 
biologic DMARDs).
Medication withdrawal and occasional therapy 
suspension
Data deﬁ ning the duration of the therapy for RA still lack. 
Currently, the medication indicated and to which the patient 
responds properly should be maintained indeﬁ nitely, at the 
physician’s discretion. In case of complete (remission) and 
sustained (for more than 6–12 months) response, gradual and 
careful drug withdrawal can be attempted at the following 
sequence: at ﬁ rst, NSAIDs; then, corticoids and biologic 
DMARDs; synthetic DMARDs should be maintained.107 
Exceptionally, if remission persists, the synthetic DMARD 
withdrawal can be carefully attempted.20 Drug-free sustained 
remission is rare, especially in patients with biomarkers such 
as anti-CCP and/or RF.
Treatment monitoring
Regarding early disease, for patients with active disease and 
symptoms up to one year, intensive follow-up is recommended 
with monthly visits and rapid medicamentous progression, 
when necessary.108,109 Therapeutic schedules and their possible 
adverse effects have already been approached in the previous 
sections.
At every visit, the efficacy and safety of the therapeutic 
intervention should be assessed, considering the patient’s 
comorbidities and aiming preferentially at remission or 
the lowest possible disease activity, as well as the im-
provement in functional capacity and quality of life. For 
patients with established disease, and especially those 
with controlled disease, the visits can be performed every 
three months.108,109 
Table 2 shows the monitoring frequency of the major pa-
rameters for properly assessing patients with RA undergoing 
treatment.
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Monotherapy 
(preferably MTX)  
 
At all phases:  
 
 Prednisone up to 15 mg/day 
or equivalent (for the 
shortest time possible) 
 
 intra articular corticoid  - 
and/or NSAIDs and 
painkillers 
 
Active disease:  
Consider CIDA aiming at remission  

















Intolerance to MTX 
Failure after 3 months 
Failure after 3 -6 months 
 
Failure of or intolerance to biologic DMARD: 
To maintain synthetic DMARD (preferably MTX)  
and change biologic DMARD to another anti-TNF 
or ABAT or RTX or TOCI 
 
Failure after 3 -6 months 
 
Combination of  
synthetic DMARDs 
 
Partial response to MTX  
Synthetic DMARD  
(preferably MTX)  
+   
Biologic DMARD  





Failure after 3 months 
Failure after 3 months 
Physical therapy and rehabilitation
During the phases of disease activity, rest helps to reduce the 
inﬂ ammatory process; however, the possibility of complica-
tions, such as joint stiffness and ﬂ exion deformities, should 
be considered.110
Kinesiotherapy can comprise passive exercises, in the 
initial phases, and active, isometric and/or isotonic, exercises. 
Those exercise programs are aimed at assuring maintenance, 
restoration, or gain of joint range of motion, muscle strength 
and stretching, aerobic capacity, and performance of speciﬁ c 
abilities.110
Most programs of dynamic exercises follow the recom-
mendations of the American College of Sports Medicine 
(ACSM).111 We recommend at least 20 minutes of exercise, 
at least twice a week, which leads to a 60% increase in the 
heart rate predicted for age, so that it can provide positive 
clinical effects with neither worsening RA activity nor 
causing pain. When dynamic exercise is compared with 
the conventional joint rehabilitation program, a signifi-
cant increase in the quality of life of patients with RA is 
observed.112–114
Aerobic activities, such as bicycle riding, jogging, running, 
water aerobics, and swimming provide better cardiovascular 
Figure 1
Flowchart for the 
medicamentous treatment 
of RA.
ABAT: abatacept; CIDA: 
compound indices of disease 
activity; DMARD: disease-
modifying antirheumatic drug; 
MTX: methotrexate; NSAIDs: 
nonsteroidal anti-inﬂ ammatory 
drugs; RTX: rituximab; TOCI: 
tocilizumab.
Mota et al.
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Table 2







Assessment every three 
months (established RA) Annual assessment
Education of patients and families X X X X X
CIDA+ X X X X X






(if negative at the ﬁ rst 
assessment, they can 
be repeated in the two 
initial years)
Conventional radiography (hands and wrists, 
feet and ankles, other joints affected) X X
Joint resonance or ultrasound 
(in doubt regarding the synovitis) X
*Assessment of  extra-articular manifestations X X X X X
**Assessment of comorbidities X X X X X
Inﬂ ammatory activity tests (ESR and CRP) X X X X X
***Laboratory assessment X X X X X
Vaccination assessment X X
**** Speciﬁ c medicamentous treatment for RA X X X X X
Medicamentous treatment of comorbidities X X X X X
PPD (or IGRA) and chest radiography 
(if a biologic DMARD, specially anti-TNF, 
is prescribed)
X
Occupational therapy X X X X X
Rehabilitation X X X X X
Evaluation of orthotic indication X X X X X
Evaluation of surgical indication X X X X X
Coordination of the multidisciplinary team X X X X X
Gestational counseling X X X X X
Evaluation of infections (clinical assessment 
and occasional complementary exams)
X
Serologies (hepatitis 
B and hepatitis C at 
the beginning of the 
investigation, HIV in 
selected situations)
X X X X
*****Evaluation and education regarding 
emergency situations X X X X X
CIDA: compound indices of disease activity (SDAI – simple disease activity index; CDAI – clinical disease activity index; DAS28 – disease activity score - 28 joints); +: for CIDA goals, see the 2011 BSR 
Consensus for diagnosis and early assessment of RA; mHAQ: modiﬁ ed health assessment questionnaire; HAQ-DI: health assessment questionnaire - disability index; ESR: erythrocyte sedimentation rate; 
CRP: C-reactive protein; PPD: tuberculin skin test; IGRA: interferon gamma release assays.
* Extra-articular manifestations: rheumatoid nodules, interstitial lung disease, serositis, ocular inﬂ ammation, and vasculitides.
**Comorbidities: arterial hypertension, cardiovascular ischemia, diabetes mellitus, atherosclerosis, low bone mass, depression, ﬁ bromyalgia, etc.
***Laboratory exams: blood count, liver function, lipid proﬁ le, and renal function; depending on the comorbidities, consider additional exams.
****Medication for RA: consider the efﬁ cacy and safety issues of each medication detailed throughout the text.
*****Urgencies on RA: scleromalacia perforans, myelopathies, multiple mononeuritis and vasculitis, pregnant patients on teratogenic drugs.
2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis
147Rev Bras Reumatol 2012;52(2):135-174
traditional treatment. Those therapies include diets, medita-
tion, biofeedback, acupuncture, massages, chiropractic, and 
homeopathy. Most of the time, scientiﬁ c studies about the 
safety and efﬁ cacy of those treatments lack.127
Patients should be instructed to always consult with their 
physicians before beginning one of those therapies. It is up to 
the physician to assess whether the intended alternative treat-
ment can harm the patient, and it is the physician’s responsibil-
ity to instruct the patient that those methods should not replace 
the traditional therapy for RA.
Managing comorbidities
Comorbidities in patients with RA are frequent and comprise 
SAH, type 2 diabetes mellitus, dyslipidemia, and osteoporo-
sis.128–130 In addition, neoplasias, infections and lung diseases, 
such as bronchiectasis and interstitial pneumonitis, are also 
more prevalent in those patients.131–134 The presence of those 
comorbidities contributes to poor quality of life and increases 
the mortality of patients with RA; thus, comorbidities should be 
diagnosed and treated in the initial phase of the disease.135 The 
management of comorbidities will be reviewed in a speciﬁ c 
recommendation by the BSR.
Treatment of the extra-articular manifestations of 
rheumatoid arthritis  
The treatment of the majority of severe extra-articular 
manifestations of RA (rheumatoid vasculitis, scleritis, 
some histological subtypes of interstitial lung disease, 
recalcitrant serositis) includes systemic corticoids (oral or 
venous) and immunosuppressive drugs, such as CF, CS, 
and AZA.136 Anecdotal evidence of clinical improvement 
of cases of rheumatoid vasculitis and lung involvement 
have been reported, but are conflicting and lack confirm-
ing studies.
Autologous cell transplantation
So far, conclusive data confirming the role of hemato-
poietic stem-cell transplantation as inductor of prolonged 
RA remission in the adult still lack.137 Because the toxic-
ity and mortality associated with the procedure are still 
significant, autologous cell transplantation in Brazil is 
reserved to severe forms, with multiple extra-articular 
manifestations, refractory to the treatments instituted and 
with risk of death.
conditioning and can aid to prevent RA-related limitation.110 
Physical means can be used as adjuncts to control pain, muscle 
contraction, and joint stiffness.115–119
Occupational therapy
Occupational therapy uses several techniques for joint pro-
tection and energy conservation. The treatment is aimed at 
reducing pain by planning stimulation activities, regular rest, 
joint motion pattern alternation, and use of orthoses and other 
devices.120
Adaptations in the household and work environment help 
to preserve the independence of individuals with RA-related 
limitations.121
Orthosis is any medical device applied to the patient’s 
body to support, align, position, immobilize, prevent or cor-
rect deformities, help with muscle strength or improve joint 
function. Orthoses reduce pain and local inﬂ ammation by 
relieving tension and load on a certain joint.121,122 The use 
of rest orthoses/braces, such as wrist brace, prevents ﬂ exion 
contractures. Functional wrist braces should be used inter-
mittently during activities for movement restriction, aiming 
at joint protection.123 Spinal orthoses are indicated to limit 
motion, especially ﬂ exion, with consequent reduction in 
pain, muscle tension and paresthesia in cases of atlantoaxial 
subluxation.120
Surgical treatment
Properly indicated surgical treatment contributes to improve 
function, mobility, pain control, and quality of life of patients 
with RA. The surgical procedures comprise the following: 
synovectomy, release of compressive neuropathies (carpal 
tunnel), tendon repair and transfer, total arthroplasty, and 
stabilization of cervical unstable vertebrae.124,125
Radiation synovectomy
Yttrium-90 (Y-90) or samarium-153 (Sm-153 PHYP) radiation 
synovectomy can be indicated, as an alternative to surgical 
synovectomy, for patients with residual synovitis in a few 
joints despite the optimization of other treatments instituted.126
Alternative therapies
Patients with chronic diseases, such as RA, frequently seek 
alternative therapies, and sometimes to the detriment of the 
Mota et al.
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PHARMACOECONOMICS' CONSIDERATIONS OF 
RHEUMATOID ARTHRITIS TREATMENT IN BRAZIL
The introduction of potent biologic DMARDs has widen 
the alternatives for the effective treatment of RA.138 
However, those drugs have substantially high costs as 
compared with those of traditional synthetic DMARDs, 
competing with the limited health resources in other es-
sential interventions. 
In general, the use of MTX, SSZ, and LEF in patients 
with active RA with no previous treatment with DMARDs 
has proved to be cost-effective as compared with the use 
of NSAIDs and corticoids in international studies.139,140 
However, the use of biologic therapy in monotherapy or in 
combination with MTX in those patients is not cost-effective as 
compared with MTX in monotherapy.139
After failing the first synthetic DMARD, the introduc-
tion of LEF can be a cost-effective strategy, because it 
delays the use of biologics.141 Similar data can be found in 
the Brazilian literature. A study using an economic model 
with Markov’s principle has reported that the use of MTX 
in monotherapy was the most cost-effective therapy in a 
48-month period.142
When the treatment with anti-TNF agents fails, RTX143 
and ABAT144 can be cost-effective. However, regarding the 
use of second and third anti-TNF agents, in that context, there 
are no randomized clinical trials providing cost-effectiveness 
analysis.
Regarding the reality of the Brazilian rheumatologi-
cal practice, Ferraz et al.145 have published the results of a 
questionnaire applied to Brazilian rheumatologists about the 
RA diagnosis and treatment. Those authors have reported 
that approximately 50% of the patients with RA are being 
properly diagnosed, and that only half of them are undergo-
ing regular treatment. The therapeutic practice in public 
and private health care services has not varied markedly. At 
both types of health care services, the most commonly used 
combined therapy (two or more DMARDs) was the MTX + 
CQD association, followed by MTX + CQD + SSZ at the 
public service, and MTX + LEF at the private service. When 
those agents failed, the most used biologic agent was IFX, 
probably because it was the only therapeutic option in the 
Brazilian Uniﬁ ed Public Health Care System (SUS) during the 
period studied. The major difﬁ culties identiﬁ ed in the patients’ 
treatment were their access to the public health care system 
and the cost of the medication in the private system. Other 
challenging aspects for the proper management of patients 
with RA at national level are the regional differences in ac-
cess to health care services, the heterogeneous distribution 
of rheumatologists in the Brazilian territory, and the few 
specialized services available.146
Pharmacoeconomic studies based on the Brazilian real-
ity need to be developed to generate information that can 
rationally guide decision making in the treatment of patients 
with RA.
SPECIAL SITUATIONS
Rheumatoid arthritis and pregnancy
RA by itself does not alter fertility, although some medications 
can reduce the ovulation rate. In addition, neither fetal nor 
maternal complications due to RA are increased, except in the 
severe forms that evolve with systemic vasculitis.147
During the gestational period, the clinical manifestations 
of RA usually improve in up to 75% of the patients, although 
90% relapse in the ﬁ rst six puerperal months.147
Most drugs used in the RA treatment are contraindicated 
during pregnancy and breast-feeding, except for HCQ and SSZ, 
which seem to be relatively safe.148–150 Patients on MTX, LEF, 
immunosuppressive agents, and biologic DMARDs should 
be instructed to use safe contraceptive methods to prevent 
pregnancy.150,151
Rheumatoid arthritis and vaccination
The overall risk of infection is known to be increased in 
RA, particularly for patients on immunobiologic agents. 
Thus, the need for vaccinating those patients should be 
considered.152–154 Before starting synthetic or biologic 
DMARDs, the patient’s vaccination status should be as-
sessed and updated. 
Vaccines that do not contain living organisms, such as the 
following, can be safely administered, and preferably 14 days 
before starting medication: anti-inﬂ uenza (IM), pneumococcal 
(7V and 23V), tetanus, diphtheria, pertussis, haemophilus in-
ﬂ uenzae type B, viral hepatitis A and B, poliomyelitis (inactive 
– IPV), meningococcal, HPV, typhoid fever (IM), and rabies. 
In a more systematic manner, most protocols recommend the 
administration of at least the following vaccines before starting 
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therapy with biologic DMARDs: inﬂ uenza (seasonal, annually, 
from April to September) and pneumococcal (initially, and 
booster dose after ﬁ ve years).154
Vaccines containing living organisms are contraindicated 
during immunosuppression and at least for three months after 
using such drugs. That group of vaccines includes the follow-
ing: MMR (measles, mumps and rubella), BCG, inﬂ uenza 
(nasal), varicella-zoster, typhoid fever, poliomyelitis (oral – 
OPV), smallpox, and yellow fever.154 However, some speciﬁ c 
situations, such as the indication of the yellow fever vaccine 
for the population living in endemic areas of the disease, should 
be considered.155,156
It is worth noting that vaccines, when indicated, should be 
administered preferably before the treatment with immunosup-
pressive agents or biologic DMARDs, because the response 
to the vaccine might be decreased.153
The management of vaccination in patients with RA will 
be reviewed in a speciﬁ c recommendation of the BSR.
Brazilian endemic diseases
Endemic-epidemic transmissible diseases, such as tuberculosis 
infection (TB), leprosy, malaria, Chagas’ disease, schistoso-
miasis, yellow fever, dengue, ﬁ lariasis, helminth infections, 
hepatitis B and hepatitis C, are still a relevant problem of 
public health in Brazil.157
Although there are few studies on the relationship between 
infectious-contagious endemicities and RA, it is worth con-
sidering that those conditions can affect both the diagnosis 
(sometimes mimicking,5 other times superimposing to the 
joint and systemic symptoms of RA, in addition to the pos-
sible occurrence of serological markers, such as anti-CCP 
and RF, in infectious diseases158) and the management of 
RA. The use of immunosuppressive therapies, especially 
biologic DMARDs, should be carefully assessed in speciﬁ c 
situations.159
Because of the high prevalence of TB in Brazil and the 
reports about TB reactivation during immunosuppressive 
treatment,104,160–164 biologic DMARDs should be carefully 
used in patients with susceptibility to TB or previous his-
tory of TB. All patients should undergo chest radiography 
and tuberculin skin test (PPD) before starting therapy.165 
The risk is higher with the use of anti-TNF therapy, es-
pecially monoclonal antibodies.166 Brazil lacks controlled 
studies on the cost-effectiveness of performing PPD in 
two steps to assess the “booster” phenomenon in patients 
with RA who will undergo biologic therapy. The PPD 
can be negative in patients with RA due to their underly-
ing immune disorder or the used therapy.167 Although in 
vitro interferon gamma release assays (IGRA), such as 
Quantiferon® or Elispot®, are promissing,168–170 because 
they are more specific, their role in investigating latent 
TB in Brazil is yet to be defined.168–171 
The use of chest high resolution computed tomography 
to investigate latent TB should be assessed in each case. 
The treatment of latent TB forms with isoniazid at the dose 
of 5–10 mg/kg/day up to the maximum dose of 300 mg/
day, for six months, should be performed in patients with 
the following characteristics: PPD reading ≥ 5 mm (or 
positive IGRA), radiological changes compatible with 
previous TB, or in patients that have had close contact with 
individuals with active TB.165,172–174 The treatment of latent 
TB forms should be initiated at least one month before 
starting the biologic DMARD. Exceptionally, however, 
their beginning can be concomitant, when the inflamma-
tory disease activity requires urgency in introducing the 
biologic therapy. Although, so far, studies have not shown 
an increase in the occurrence of TB cases with the use of 
non-anti-TNF biologic DMARDs, screening for latent 
infection is recommended. 
In addition to HIV, viral hepatitis B and viral hepatitis C 
should be investigated prior to the use of biologic DMARDs. 
If those viral infections are present, biologic DMARDs should 
be avoided. In exceptional cases of infection by hepatitis C 
virus, biologic DMARDs can be used associated with the 
antiviral treatment.175,176
Speciﬁ c infections, such as Chagas’ disease, should be inves-
tigated in endemic regions. In addition, routine dental assessment 
and care are recommended before and during treatment, for the 
prevention and treatment of periodontal infections.177
BSR RECOMMENDATIONS FOR TREATING 
RHEUMATOID ARTHRITIS
Based on the above considerations and on the peculiar 
aspects of the Brazilian socioeconomic reality, the expert 
members of the Rheumatoid Arthritis Committee of the 
Brazilian Society of Rheumatology have proposed the rec-
ommendations summarized in Table 3 for treating patients 
diagnosed with RA.
Mota et al.
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CONCLUSIONS
This consensus aimed at elaborating recommendations for the 
treatment of RA in Brazil, considering the characteristics of 
the country, such as drug availability, socioeconomic level of 
the population, pharmacoeconomic aspects, and the occurrence 
of several endemic diseases.
Despite the recent publication of the North-American and 
European guidelines for the treatment of RA, it is worth review-
ing the subject, considering speciﬁ c aspects of the Brazilian 
Table 3
Recommendations of the Brazilian Society of Rheumatology for the treatment of rheumatoid arthritis
Recommendation 1: Before any type of treatment, patients should be instructed about their disease, and, particularly, about the possible evolution and prog-
nosis. The treatment decision should be shared with patients.
Recommendation 2: Immediately after the diagnosis, a DMARD should be prescribed and the treatment should be adjusted aiming at achieving remission or 
low disease activity (according to CIDA) at frequent clinical assessments, within 30–90 days.
Recommendation 3: The treatment for RA should be conducted by a rheumatologist, who is the specialist with the greatest knowledge about the therapeutic 
options available, their indications and adverse effects.
Recommendation 4: The ﬁ rst-line treatment comprises synthetic DMARDs, such as MTX, LEF, and SSZ. The antimalarials HCQ and CQD are less effective and 
should be reserved for mild disease forms and with low erosive potential. CS or parenteral gold can be used on exceptional conditions.
Recommendation 5: MTX is the drug of choice for treating RA, but, if contraindicated and/or at the physician’s discretion, other synthetic DMARDs can be 
used as ﬁ rst choice. Combinations of synthetic DMARDs can be prescribed, even as the ﬁ rst option, for established RA with predictors of poor prognosis.
Recommendation 6: Patients who failed to achieve a response, characterized as clinical remission or at least low disease activity (according to assessment 
by use of one of the CIDA) after at least two schemes of synthetic DMARDs, including at least one combination of synthetic DMARDs, should be assessed 
regarding the use of biologic DMARDs. 
Recommendation 7: Exceptionally, for patients combining characteristics of worse prognosis and rapidly progressive disease, biologic DMARDs can be 
considered after one single scheme of synthetic DMARDs.
Recommendation 8: The use of anti-TNF agents (ADA, CERT, ETN, IFX, or GOL) is preferentially recommended as initial biologic therapy. However, in the 
presence of contraindications or in certain clinical situations, biologic therapy can be initiated with other biologic DMARDs, such as B lymphocyte depletion 
agents (RTX), T lymphocyte costimulation modulators (ABAT), and antibodies against the IL-6 receptor (TOCI).
Recommendation 9: After therapeutic failure to respond to the ﬁ rst biologic DMARD (anti-TNF or not), other biologic DMARDs (anti-TNF or not) can be used. 
It is up to the physician to choose the biologic DMARD to be used in patients who failed to respond to a biologic DMARD.
Recommendation 10: CF and AZA can be used in patients with severe extra-articular manifestations, such as vasculitis and/or lung involvement.
Recommendation 11: The intra-articular use of a corticoid is useful at any time during treatment. The oral use of a corticoid has a DMARD effect and improves the 
clinical response at the initial phase, but it should be used at low doses (< 15 mg/day of prednisone or equivalent) and for the shortest period of time necessary. 
Recommendation 12: NSAIDs are useful to reduce the inﬂ ammatory process and pain, mainly at the initial phase of disease, but should always be prescribed 
in association with a DMARD.
Recommendation 13: At the beginning of the RA treatment, the patient should be preferably assessed monthly. Patients whose disease is under control can 
be assessed at longer intervals of up to three months.
Recommendation 14: Physical therapy, rehabilitation and occupational therapy are indicated from the patient’s initial assessment onwards. 
Recommendation 15: Surgical treatment, when properly and opportunely indicated, contributes to improve the function, motion, pain control, and quality 
of life of patients with RA. 
Recommendation 16: It is recommended that patients be instructed to always consult with their physician before starting an alternative therapy (acupuncture, 
diet therapy, homeopathy, phytotherapy). The physician should assess whether the intended  alternative treatment can induce any damage to the patient and 
instruct him/her not to replace traditional therapy for RA with the alternative therapy.
Recommendation 17: Patients should be educated regarding family planning, adequate time for pregnancy (based on disease activity and use of medications), 
and effective contraceptive methods for women on teratogenic drugs, such as MTX and LEF.
Recommendation 18: The active search for and adequate management of comorbidities (SAH, diabetes mellitus, dyslipidemia) should be performed, because 
comorbidities contribute to decrease the quality of life and increase the mortality of patients with RA.
Recommendation 19: Before initiating synthetic or biologic DMARDs, the patient’s vaccination chart should be assessed, and the indicated vaccines should 
be administered, preferably prior to treatment with immunosuppressors or biologic agents, because the response to vaccine can be reduced.
Recommendation 20: Endemic-epidemic transmissible diseases in Brazil, such as tuberculosis infection, leprosy, malaria, Chagas’ disease, schistosomiasis, 
yellow fever, dengue, ﬁ lariasis, and helminth infections, should be assessed and properly treated in patients with RA. 
reality. Thus, the ﬁ nality of establishing consensual guidelines 
for treating RA in Brazil is to support Brazilian rheumatolo-
gists, by using the evidence obtained in scientiﬁ c studies and 
the experience of an expert committee to homogenize the thera-
peutic approach of RA, within the Brazilian socioeconomic 
context, maintaining the physician’s autonomy to indicate/
choose between the therapeutic alternatives available. 
Because of the rapid advance of knowledge in this science 
ﬁ eld, we suggest these recommendations be updated every 
two years.
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